Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
29.21
0.00 (0.00%)
At close: Oct 21, 2026, 4:00 PM EDT
29.25
+0.04 (0.14%)
After-hours: Oct 21, 2026, 6:08 PM EDT
Hims & Hers Health Revenue
Hims & Hers Health had revenue of $753.21M in the quarter ending June 30, 2026, with 38.25% growth. This brings the company's total for the last twelve months to $2.58B, up 28.04% year-over-year. In the year 2025, Hims & Hers Health had annual revenue of $2.35B with 59.00% growth. That makes Hims & Hers Health the 4,221st largest company in the world by revenue and 1,146th in the United States.
Revenue (ttm)
$2.58B
Revenue Growth
+28.04%
P/S Ratio
2.64
Revenue / Employee
$1,055,738
Employees
2,442
Market Cap
6.82B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Hims & Hers Health breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.35B | 871.12M | 59.00% |
| Dec 31, 2024 | 1.48B | 604.51M | 69.33% |
| Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
| Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
| Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
| Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
| Dec 31, 2019 | 82.56M | 55.88M | 209.45% |
| Dec 31, 2018 | 26.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| Amneal Pharmaceuticals | 3.12B |
| Alkermes | 1.67B |
| Lantheus Holdings | 1.56B |
| Indivior Pharmaceuticals | 1.33B |
| Kiniksa Pharmaceuticals International, | 840.85M |
HIMS News
- 9 hours ago - Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men's Health Launch to Date - Business Wire
- 1 day ago - Hims & Hers stock rises 5% as company launches men's weight care in Germany - Invezz
- 1 day ago - Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors With Significant Losses to Take Action Before the November 2, 2026 Lead Plaintiff Deadline - Newsfile Corp
- 1 day ago - What Does Hims & Hers Health, Inc.'s 14.73% Stock Drop Mean for Investors? The Law Offices of Howard G. - PRNewsWire
- 7 days ago - Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Act Ahead of the Lead Plaintiff Deadline on November 2, 2026 - GlobeNewsWire
- 9 days ago - Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026 - Business Wire
- 9 days ago - Hers Launches in Australia, Built to Care for the Whole Woman - Business Wire
- 13 days ago - Kaplan Fox & Kilsheimer LLP Encourages Hims & Hers Health, Inc. (HIMS) Investors With Losses to Seek Appointment as Lead Plaintiff Before November 2, 2026 - Newsfile Corp